Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121–3127.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhnai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhn E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good prognosis diffuse large B-cell lymphoma: 6-year results of an open-label randomized study of the Mabthera International Trial (MLnt) Group. Lancet Oncol 2011;72:1013–1022.
   Web of Science ®Google Scholar
• Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012;17(Suppl. 1):S93–S97.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquieres H, Witzig TE, et al. Diagnosed diffuse large B-cell lymphoma patients treated with immunochemotherapy who are alive and progression free 12 months after diagnosis have a subsequent overall survival similar to that of the general population. Blood 2012;120(Suppl. 1): Abstract 1540.
   Google Scholar
• Feng J, Wang Z, Guo X, et al. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol 2012;95:143–148.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Bari A, Sacchi S, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma:a large multicenter study involving 1191 patients, in pre and post rituximab era. Haematologica 2014;99:125–130.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann T, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large B-cell lymphoma. Leukemia 2011;25: 1502–1509.
   PubMed Web of Science ®Google Scholar
• Batty N, Ghonimi E, Feng L, et al. The absolute monocyte and lymphocyte prognostic score for patients with diffuse large B-cell lymphoma who received R-CHOP. Clin Lymphoma Myeloma Leuk 2013;13:15–18.
   PubMed Web of Science ®Google Scholar
• Keane C, Gill D, Vari F, et al. CD4 + tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 2013;88: 273–276.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012;97:262–269.
   PubMed Web of Science ®Google Scholar
• Koh YW, Kang HJ, Parck C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012;17:871–880.
   PubMed Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PloS One 2012;7:e41658.
   PubMed Web of Science ®Google Scholar
• Rambaldi AM, Caracciolo D, Laditto M, et al. The lymphocyte-to-monocyte ratio improves the IPI risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol 2013;88:1062–1067.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin's lymphoma. Blood Cancer J 2013;3:e110.
   Web of Science ®Google Scholar
• Cox DR, Habermann TM, Payne BA, et al. Evaluation of the Coulter counter model S-Plus IV. Am J Clin Pathol 1985;84:297–306.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34:187–202.
   Google Scholar
• Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B-cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010;51:199–212.
   PubMed Web of Science ®Google Scholar
• Kohave R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: International Joint Conference on Artificial Intelligence (IJCAI),1995. Available from: robotics.stanford.edu/˜ronnyk/accEst.ps
   Google Scholar
• Hands S, Everitt B. A Monte Carlo study of the recovery of cluster structure in binary data by techniques clustering techniques. Multivariate Behav Res 1987;22:235–243.
   PubMed Web of Science ®Google Scholar
• Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol 2007;122:220–228.
   PubMed Web of Science ®Google Scholar
• Li YL, Pan YY, Jiao Y, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B-cell lymphoma after standard first line regimens. Ann Hematol 2031 Oct 19. [Epub ahead of print]
   Google Scholar
• Tadmor T, Bari A, Sacchi S, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study including 1911 patients in the pre-and post-rituximab era. Haematologica 2014;99:125–130.
   PubMed Web of Science ®Google Scholar
• Sun D, Elson P, Liedtke M, et al. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 2012:87:957–960.
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• Chae YS, Shin H, Sohn SK, et al. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, Adriamycin, vincristine and prednisone. Leuk Lymphoma 2012; 53:1757–1763.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classical Hodgkin's lymphoma. N Engl J Med 2010; 362:875–885.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E, et al. Macrophages and tumor angiogenesis. Leukemia 2007;21:2085–2089.
   PubMed Web of Science ®Google Scholar
• Green CE, Liu T, Montel V, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis, and neovascularization. PloS One 2009;4:e6713.
   Web of Science ®Google Scholar
• Roca H, Varsos ZS, Sud S, et al. CCL2 and interleukin 6 promote survival of human CD11 b+ peripheral blood mononuclear cells and induce M2-type macrophages polarization. J Biol Chem 2009; 284:34342–34354.
   PubMed Web of Science ®Google Scholar
• Stiff P, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369:1681–1690.
   PubMed Web of Science ®Google Scholar